Shaping the Future of Liver Research and Toxicology

Fully functional iPSC-derived hepatocyte models (Opti-HEP) for generating pre-clinical human data

Discover More

Recent News

DefiniGEN / Fri, Sep 27, 2024
DefiniGEN secures ISO 9001:2015 recertification
Read More

Upcoming Events

BIO-Europe 2024
4-6 November 2024 / Stockholm, Sweden
Read More

 

Enabling cures for liver disease through highly predictive in vitro modeling

We generate high-quality, phenotypically relevant disease modeled hepatocytes that can be utilized to screen compounds.

Opti-HEP - Human Hepatocyte-Like Cells

Physiologically relevant liver disease models that can be generated at scale for disease modeling, assay development and screening applications.

 

Learn more >

 

 

+
SB1_0941-1

Disease Modeling

DefiniGEN's platform technology enables the generation of predictive and phenotypically relevant iPSC-derived human disease models for a wide range of metabolic and liver diseases which can be produced at scale.

Learn more >

+
disease-modelling-image

Profiling Molecules

Combine our expertise at generating iPSC-derived hepatocyte disease models with our wide panel of bespoke bioassays. We work as partners with your team to design and implement in-house screening of small molecules and advanced genetic therapies, so you can advance your program at speed.

Learn more >

+
phenotypic-screening-image

Donor Variance Panel

DefiniGEN has a large panel of iPSC lines allowing us to offer all our disease models and cell-based bioassays  in donors ranging in gender, age and ethnicity.  Researchers use our donor panels to further screen their lead candidates and potentially inform the stratification of a successful clinical trial.

 

Learn more >

=
SPB_4293

Specialist CRO focused on delivering liver and metabolic disease models

icons_dark blue2
Highly Predictive

Opti-HEPs successfully recapitulate key aspects of disease pathophysiology across a wide-range of conditions that affect different aspects of liver function.

icons_dark blue3
Scalable

 

DefiniGEN’s proprietary differentiation protocol permits large-scale generation of hepatocyte-like cells with field leading purity and functionality.

icons_dark blue
Optimized Bioassay Development

Optimized bioassays that can accurately evaluate compound potency, efficacy and delivery.

Scientific expertise

15
Successful and recurring partnerships with leading cell and gene therapy companies 
10
10 years of iPSC
innovation
6
in-house validated disease models ready for screening 
10
10 years of supporting R&D with our innovative, proprietary iPSC endodermal protocols
definigen-logo-background-overlay
Advance your scientific discoveries with our tailored disease modeling products and services.
Screening Services
Disease Modeling